Crown Bioscience offers immuno-oncology translational research platform

Crown Bioscience president Jean-Pierre Wery said: "Crown’s suite of in vitro and in vivo immuno-oncology assays employing translational experimental models help inform and accelerate the development of cancer immunotherapies and move the best candidates forward to clinical trials."

Crown’s in vitro immuno-oncology assays, including immunophenotyping and immuno-functional assays, help scientists validate immuno-oncology targets, screen for immuno-modulating agents, understand mechanisms of actions and identify biomarkers.

With one of the world’s largest collections of validated in vivo syngeneic cell line models, as well as primary allografts of tumors, Crown helps scientists evaluate and understand novel anticancer compounds.

"In addition, we provide the unique capability to combine image-guided micro-irradiation with our syngeneic models to explore combination therapeutic strategies involving targeted irradiation with immunotherapies," Wery added.

Crown also provides various humanized immuno-oncology in vivo models, including the MiXeno platform of transient human immunity by mixing human peripheral blood mononucleated cells (PBMC) with xenograft models for testing human biological-based immunotherapeutics for cancers, providing a simple, cost-effective alternative to full hematopoietic stem cell reconstitution.

Crown’s other humanized immuno-oncology technologies under development include HuGEMM with knocked-in human checkpoint targets, e.g., huPD1 and huCTLA4, into immunocompetent models and PDX in human hematopoietic stem reconstituted models, both of which will be extremely valuable in evaluating human biologicals for immunotherapies.

Crown’s industry-leading translational models include a unique collection of HuPrime cancer models available through its HuBase annotated database for researchers to predict and guide clinical development.

Crown’s proprietary genetic signature technology (HuSignature) helps to identify predictive biomarkers (HuTrial), which can be used to predict success in the clinic and guide development using the signature derived companion diagnostics.